window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-169295030-1');

News

News2020-09-03T13:04:33+03:00

EnzyQuest, member of a consortium awarded with €2.4M EU funding (H2020)

We are excited to announce that an eight-partner consortium (IRIS-COV), of which we are members, has been awarded an EU funding of €2.4 M (H2020-SCI-PHE-CORONAVIRUS-2020-2). The “IRIS-COV” project is one of the 23 to receive funding from a total of 454 submitted proposals.

The aim of the project is the market release of a portable device to carry out a combined test for SARS-CoV-2 and Influenza A at the point-of-care (POC). EnzyQuest is actively engaged in manufacturing and large-scale production of reagent-kits. In addition to EnzyQuest, the consortium includes BIOPIX-T (Crete, Greece) which is the medical device designer, manufacturer and provider, IMBB-FORTH (Crete, Greece) which will coordinate the project, three hospitals in Europe (UCLH-UK, INSERM-France and ULB-Belgium) which will perform the clinical validations, one consulting company for the certification (PKNM-Switzerland) and an end-user in South Africa (Kiara Health).

September 3rd, 2020|Categories: Achievements, Company, Grants|
Go to Top